Abstract: An article of manufacture comprises a copolymer of ethylene and vinyl aromatic monomer having a molecular weight of less than 15,000. Preferably, the copolymer is characterized by a backbone having a first and second terminal end group, the first terminal end group is a methyl group, the second terminal end group is a vinyl group, wherein the ratio of the terminal methyl group to the terminal vinyl group is 0.8:1 to 1:0.8. The article of manufacture includes, but is not limited to, waxes, lubricants, additives, etc. The waxes may be used to formulate paints and coatings, printing inks, carbon paper, photo toners, building and construction materials, mold release agents, hot melt adhesives, candles. The waxes may also be used in wood processing, metal working, powder metallurgy and sintering, wax modeling, sizing, crop protection, and so on.

Abstract: An asymmetric siloxane is made by reacting a silicone having the formula MHDxM?H where MH is R1R2HSiO1/2, M?H is R4R5HSiO1/2 and x is an integer 0?x?10 under selective hydrosilylation conditions in the presence of a precious metal hydrosilylation catalyst, with a first olefine compound and in a second step, a monohydridosiloxane produced in the first step is reacted under hydrosilylating condtions with another olefine compound different from the first olefine compound.

Abstract: A silane-modified phenolic resin is prepared by reacting a phenolic compound (e.g., resorcinol) with an aldehyde to produce a phenolic novolak resin. The phenolic novolak resin is further reacted with at least one silane compound to produce the silane-modified phenolic resin. The reaction is typically carried out in the presence of an acid or base catalyst. The resulting resin has a lower softening point and can be used as a methylene acceptor compound in a vulcanizable rubber composition.

Abstract: Golf balls comprising elastomer compositions are presently disclosed. These elastomer compositions comprise at least one polyamine having the structure: where R1 and R2 are the same or different radicals chosen from hydrogen and C1-C60 organic moieties: Z1 is chosen from halogens and C1-C60 organic radicals: and Z2, Z3 and Z4 are the same or different radicals chosen from hydrogen, halogens, and C1-C60 organic radicals. These elastomer compositions can be used in any one or more portions of the golf balls, such as inner core layer, intermediate core layer, outer core layer, intermediate layer, cover, inner cover layer, intermediate cover layer, and/or outer cover layer.

Abstract: A process for the production of polycarbonate having increased end-cap levels, the process comprising adding a terminal blocking agent of the formula: wherein R1 is a propoxy or butoxy and R2 is selected from the group consisting of C1-C30 alkyl, C1-C30 alkoxy, C6-C30 aryl, C7-C30 aralkyl, and C6-C30 aryloxy.

Abstract: A water soluble polymer is provided having two or more oligomers linked to each other by hydrolytically degradable carbonate linkages. The polymer can be hydrolytically degraded into oligomers (e.g., oligomers of ethylene oxide) under physiological conditions. The polymer can be conjugated to biologically active agents such as proteins or peptides to impart improved water solubility, reduced immunogenicity, reduced rate of renal clearance, and increased stability. The polymer is useful in making hydrolytically degradable hydrogels which can be used in drug delivery and related biomedical applications. On example of the polymer is a poly (ether carbonate) of the formula X—O—[(—CH2CH2-O-)n—CO2—]n—(CH2CH2))n -y where X and Y are independently H, alkyl, alkenyl, aryl, or a reactive moiety, and at least one of X and Y is a reactive moiety.

Abstract: Disclosed are polyphosphazenes of Formula 1 showing a sol-gel behavior with a temperature change, a preparation method thereof, and injectable thermosensitive polyphosphazene hydrogels using the same

Abstract: The present invention is related to a series of polyesters based upon the reaction of dimer acid, dimer alcohol and Guerbet alcohol. The resulting polyester is a high molecular weight product that is well tolerated by the skin and has outstanding emolliency. The Guerbet alcohol, being mono hydroxyl is a capper portion of the polymer, the dimer alcohol is a chain extender having two hydroxyl groups and the dimer acid is a diacid that reacts with the hydroxyl groups on the Guerbet and dimer alcohol to make the polyester.

Abstract: The invention relates to a method for producing high-molecular weight polyesters, such as e.g. polyethylene terephthalate (PET), polybutylene terephthalate (PBT), polynaphthalene terephthalate (PEN), polytrimethylene terephthalate (PTT) and/or polyesters of other dicarboxylic acids and diols including copolymers thereof. The invention relates likewise to a device for implementing this method. The latter concerns a single-stage tower reactor with which a method, comprising only two reactors, is made available for the total process.

Abstract: A technique is described for the preparation of polymers according to a process in which the starting compound of formula (I) is polymerized in the presence of a base in an organic solvent. No end chain controlling agents are required during the polymerization to obtain soluble precursor polymers. The precursor polymer such obtained comprises structural units of the formula (II). In a next step, the precursor polymer (II) is subjected to a conversion reaction towards a soluble or insoluble conjugated polymer by thermal treatment. The arylene or heteroarylene polymer comprises structural units of the formula III. In this process the dithiocarbamate group acts as a leaving group and permits the formation of a precursor polymer of structural formula (II), which has an average molecular weight from 5000 to 1000000 Dalton and is soluble in common organic solvents.

Abstract: The present invention is generally directed to perfluoroalkylated fluorene polymers. It further relates to a process for preparing the polymers and devices that are made with the polymers.

Abstract: A PBI compound includes imidazole nitrogens at least a portion of which are substituted with an organic-inorganic hybrid moiety. At least 85% of the imidazole nitrogens may be substituted. The organic-inorganic hybrid moiety may be an organosilane moiety, for example, (R)Me2SiCH2— where R is selected from among methyl, phenyl, vinyl, and allyl. The PBI compound may exhibit similar thermal properties in comparison to the unsubstituted PBI. The PBI compound may exhibit a solubility in an organic solvent greater than the solubility of the unsubstituted PBI. The PBI compound may be included in separatory media. A substituted PBI synthesis method may include providing a parent PBI in a less than 5 wt % solvent solution. Substituting may occur at about room temperature and/or at about atmospheric pressure. Substituting may use at least 5 equivalents in relation to the imidazole nitrogens to be substituted or, preferably, about 15.

Abstract: A method for the extraction, separation, fractionation and purification of biopolymers from plant materials using supercritical and/or subcritical solvent extractions is disclosed. Specifically, the process can be used for the separation of resins and rubber from guayule shrub (Parthenium argentatum), and other rubber and/or resin containing plant materials, using supercritical solvent extraction, for example supercritical carbon dioxide extraction. Additionally, polar and/or non-polar co-solvents can be used with supercritical carbon dioxide to enhance the selective extraction of resins and rubbers from the shrub.

Abstract: The invention is directed to preferred repeat sequences of Neural Thread Protein (NTP), peptides, mimetics, antibodies, and nucleic acids of the preferred sequences, and diagnostic and therapeutic methods of using such preferred NTP sequences.

Abstract: The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.

Abstract: The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.

Abstract: Isolated peptides are disclosed which, when processed, generate a coordinated immune response.

Abstract: Disclosed herein is a novel retinoblastoma binding protein-related gene that encodes an antigenic epitope, IKPSLGSKK (SEQ ID NO:3), which is differentially expressed in cancers, such as breast, lung, colon, pancreas, and ovarian cancer. Polynucleotides that encode and polypeptides that comprise the antigenic epitope and variants thereof are disclosed. Also, disclosed are methods of using the polynucleotides and polypeptides of the present invention in immunotherapies and immunoassays.

Abstract: Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disulfide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The structure and specificity of a recombinant ?2,3-sialyltransferase from Campylobacter spp., is disclosed. Also provided are methods for using the ?2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase.

Abstract: The invention provides an isolated squirrel monkey prokineticin receptor 2 (PKR2) polypeptide containing the amino acid sequence referenced as SEQ ID NO:2. The invention also provides an isolated chimpanzee PKR2 containing the amino acid sequence referenced as SEQ ID NO:4. Also provided are methods of identifying PKR2 agonists and antagonists using the squirrel monkey PKR2 polypeptide. Additionally, the invention provides an isolated rhesus monkey PK2 polypeptide containing the amino acid sequence referenced as SEQ ID NO:6. Nucleic acid molecules encoding the disclosed polypeptides further are provided by the invention.

Abstract: The present invention relates to polynucleotide molecules comprising nucleotide sequences encoding an aveC gene product, which polynucleotide molecules can be used to alter the ratio or amount of class 2:1 avermectins produced in fermentation cultures of S. avermitilis. The present invention further relates to vectors, host cells, and mutant strains of S. avermitilis in which the aveC gene has been inactivated, or mutated so as to change the ratio or amount of class 2:1 avermectins produced.

Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such as E. coli thioredoxin or a modified E. coli thioredoxin, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies. The methods of the present invention facilitate the rapid isolation and purification of recombinant proteins. In addition, the present methods may be useful for producing polypeptides or proteins which are small and are typically difficult to express, as well as those proteins that are toxic to host cells such as E. coli. The present invention also provides plasmids, vectors and host cells to be used in the present invention for production of polypeptides, and methods of production of polypeptides using these vectors and host cells.

Abstract: A process for isolation of milk osteopontin from a material containing milk osteopontin by optionally mixing the milk material with a calcium source and separate the osteopontin containing phase from the rest of the milk material by pH adjustment.

Abstract: The present invention provides a human polypeptide homolog of DBF4/ASK1 (for “Activator of S phase kinase”) and polynucleotides which identify and encode DRF1 (for “DBF4 Related Factor 1”). In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of DRF1 or DRF1-containing complex agonists/antagonists, useful for the treatment of human diseases and conditions.

Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, immunoadhesins, agonists and antagonists (including antibodies) to human & vertebrate fused.

Abstract: The presented invention relates to monoclonal antibodies useful in sensitive and specific immunological assays for the identification of prions in various tissues and body fluids, the production of such monoclonal antibodies by means of immunization of PrP0/0 mice by means of a new recombinant fragment of PrP and the use of the antibodies, e.g. for therapeutic and preventive treatments of humans and animals suffering from prion diseases.

Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.

Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

Abstract: Improved synthesis methods are provided for preparing conjugates of proteins and chelating agents. In the synthesis methods, non-stable bonds are hydrolyzed after the conjugate is synthesized, for example by treating the conjugate with a quenching agent. The synthesis method provides conjugates that are substantially free of non-stable bonds between the protein and the chelating agent, such that the chelating agent is less likely to dissociate with the conjugate after the conjugate has been stored for extended periods. The conjugate may be useful for therapeutic or diagnostic methods.

Abstract: A C-nitroso compound having a molecular weight ranging from 225 to 1,000 (from 225 to 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained by nitrosylation of a carbon acid having a pKa less than about 25, is useful as an NO donor. When the compound is obtained from a carbon acid with a pKa less than about 10, it provides vascular relaxing effect when used at micromolar concentrations and this activity is potentiated by glutathione to be obtained at nanomolar concentrations. When the compound is obtained from a carbon acid with a pKa ranging from about 15 to about 20, vascular relaxing effect is obtained at nanomolar concentrations without glutathione. In another embodiment, a biocompatible polymer incorporates a C-nitroso moiety.

Abstract: The 3? untranslated region of the human prohibitin gene has been isolated for use in a cancer susceptibility screen and as a therapeutic agent for the treatment of cancer.

Abstract: The invention provides methods of detecting a nucleic acid. The methods comprise contacting the nucleic acid with one or more types of particles having oligonucleotides attached thereto. In one embodiment of the method, the oligonucleotides are attached to nanoparticles and have sequences complementary to portions of the sequence of the nucleic acid. A detectable change (preferably a color change) is brought about as a result of the hybridization of the oligonucleotides on the nanoparticles to the nucleic acid. The invention also provides compositions and kits comprising particles. The invention further provides methods of synthesizing unique nanoparticle-oligonucleotide conjugates, the conjugates produced by the methods, and methods of using the conjugates. In addition, the invention provides nanomaterials and nanostructures comprising nanoparticles and methods of nanofabrication utilizing nanoparticles. Finally, the invention provides a method of separating a selected nucleic acid from other nucleic acids.

Abstract: The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.

Abstract: The invention relates to mutant nuclear hormone receptors that encode mutant nuclear hormone receptors, in which particular amino acid residues are substituted with respect to wild type, so as to be able to detect ligand binding to the mutant receptor by either a change in a physical property of the mutant receptor and/or an transcriptional induction of a nuclear hormone receptor construct. The invention also relates to a nuclear hormone receptor response element denoted by the formula YDRXZ comprising a direct repeat (DR) comprising two half sites separated by X nucleic acid bases; wherein Z indicates the presence of at least one DR oriented in either a forward or reverse orientation; wherein Y equals 1 to 8 forward and/or reverse direct repeats; and X equals 1 to about 12.

Abstract: The promoter regions associated with the Yarrowia lipolytica glyceraldehyde-3-phosphate dehydrogenase (gpd) and phosphoglycerate mutase (gpm) genes have been found to be particularly effective for the expression of heterologous genes in oleaginous yeast. The promoter regions of the invention have been shown to drive high-level expression of genes involved in the production of ?-3 and ?-6 fatty acids.

Abstract: The invention provides primers designed on base of the difference of sequences among staphylococcal enterotoxin subtypes, i.e., C1, C2 and C3. The invention also provides a PCR method for detecting subtypes of staphylococcal enterotoxin type C by using the above-mentioned primers. The invention relates also to DNA probes useful for the identification of subtypes C1, C2 and C3 of staphylococcal enterotoxin type C in various food and clinical samples. The primers of the invention comprises following sequences: ENTC1 5?-ACAGA GTTAT TAAAT GAAGG-3?; ENTC2 5?-GTATC AGCAA CTAAA GTTAT-3?; ENTC3 5?-AAGAG ATTAT TTATT TCACGT-3?; ENTCR 5?-ATCAT ACCAA AAAGT ATTGC-3?.

Abstract: The present invention relates to a new, particularly economical process for preparing particulate water-soluble cellulose derivatives. The process involves forming a feed composition of swollen and/or dissolved cellulose derivative, and water. The feed composition is contacted with a superheated gas mixture, in a sieve-free high rotational speed gas jet impact mill, and the cellulose derivative of the feed composition is converted into a solid state form of finely particulate particles. The superheated gas mixture, with which the feed composition is contacted, is selected from: (i) a superheated gaseous mixture of steam and an inert gas; and (ii) a superheated gas mixture of steam and air. The superheated gas mixture has a steam content of 40 wt. % to 99 wt. %, based on the total weight of the superheated gas mixture.

Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.

Abstract: Reactive dyes of formula (1): wherein R1, is optionally substituted C1-C4 alkyl, R2 is halogen, C1-C4 alkyl, C1-C4 alkoxy or sulfo, Z1 is a radical of formula —SO2—Y (2a), —CO—NH—(CH2)K—SO2—Y (2b), —NH—CO—CH(Hal)—CH2—Hal (2c) —NH—CO—C(Hal)?CH2 or (2d) wherein Hal is chlorine or bromine, Y is vinyl or a radical —CH2CH2—U and U is a group removable under alkaline conditions, k is the number 2, 3, 4, 5 or 6, n is the number 0, 1 or 2 and m is the number 0 or 1, are suitable for dyeing or printing cellulose-containing fibre materials, preferably natural or synthetic polyamide fibre materials, and produce, with a high colour yield, dyeings and prints having good fastness properties

Abstract: An optical recording medium containing one or more compounds selected from imide compounds having a metallocene residue in a recording layer and an imide compound represented by a general formula (1): wherein a ring AR represents a substituted or unsubstituted aromatic ring residue or a residue formed by combining two or more aromatic ring residues via one or more linking groups; n represents the number of imide groups bonded to the ring AR; Am represents any one of substituents A1 to An bonded to a nitrogen atom of each imide group; and m represents an integer of from 1 to n, with the proviso that at least one substituent selected from the group consisting of A1 to An is one having at least one substituted or unsubstituted metallocene residue.

Abstract: Processes for separation of enantiomers of clopidogrel, and converting one enantiomer of clopidogrel to another enantiomer of clopidogrel are provided. The enantiomers are separated by crystallizing the (S) enantiomer as camphor sulfonate salt from a hydrocarbon, or a mixture of a hydrocarbon and a co-solvent, preferably DMF:toluene. The (R) enantiomer is then racemized and recycled by reaction with a catalytic amount of a base, preferably with t-butoxide.

Abstract: There are presented compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms thereof, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

Abstract: The invention relates to methods of synthesizing 2-substituted azole compunds of formula (I): The invention is also relates to compounds of formula (I) and to intermediate compounds in the synthesis method.

Abstract: The present invention relates to the preparation of 3-methylamino-1-(2-thienyl)-1-propanone and its use for preparing the pharmaceutical (+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate—(trade name Duloxetine®).

Abstract: 4-Substituted coumarin compounds having the general formula of where R is H, CHO, OCH3, X, NO2, an alkyl having C1-10, —OCH2O—, an aryl being mono- or poly-substituted with CN or COOCH3 with the aryl being a phenyl, naphthyl, or azaryl, or a coumarin group that is substituted with R1, R2, R3, R4, with R1, R2, R3, and R4 being H, an alkyl having C1-10, X, NO2, CN, OCH3, COOCH3 or OR5, R5 being H or an alkyl having C1-10, and X being a halogen.

Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.

Abstract: The invention relates to difluorobenzo-1,3-dioxoles, to a process for their preparation, and to their use for preparing medicaments and crop protection agents.

Abstract: This invention relates to methods for purification of paclitaxel from a paclitaxel-containing material. The method comprises the following steps: (a) extracting a paclitaxel-containing material with an organic solvent to obtain an extract, and concentrating the extract; (b) adding the concentrate with an organic solvent which is not mixed with water to separate an organic solvent phase and then concentrating; (c) subjecting the concentrate to normal phase chromatography to obtain an eluate; (d) dissolving the eluate in an acetone or dichloromethane followed by adding pentane or hexane to form a precipitate; and (e) subjecting the precipitate to high performance liquid chromatography. According to the method of the present invention, paclitaxel of over 99.5% purity can be easily obtained from a Taxus genus plant with a high yield.